Clinical Trial Update: A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® [Phase 3]

View source ↗

Summary

A phase 3 trial comparing a biosimilar denosumab to Prolia in postmenopausal osteoporosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Biosimilar Denosumab (denosumab)
• Prolia (denosumab)

Snippet

Sponsor: Enzene Biosciences Ltd. | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2026-02-10